stoxline Quote Chart Rank Option Currency Glossary
Prothena Corporation plc (PRTA)
34.89  2.31 (7.09%)    12-01 16:00
Open: 32.46
High: 34.94
Volume: 805,640
Pre. Close: 32.58
Low: 31.96
Market Cap: 1,874(M)
Technical analysis
2023-12-01 4:22:08 PM
Short term     
Mid term     
Targets 6-month :  43.45 1-year :  47.42
Resists First :  37.2 Second :  40.59
Pivot price 33.55
Supports First :  31.7 Second :  26.38
MAs MA(5) :  33.09 MA(20) :  34.05
MA(100) :  49.9 MA(250) :  55.41
MACD MACD :  -2 Signal :  -2.5
%K %D K(14,3) :  27.8 D(3) :  19.3
RSI RSI(14): 46.6
52-week High :  79.65 Low :  28.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PRTA ] has closed below upper band by 16.2%. Bollinger Bands are 57% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 34.97 - 35.22 35.22 - 35.41
Low: 31.53 - 31.77 31.77 - 31.96
Close: 34.55 - 34.95 34.95 - 35.27
Company Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Headline News

Sun, 03 Dec 2023
Prothena (NASDAQ:PRTA) shareholder returns have been strong ... - Yahoo Finance

Wed, 01 Nov 2023
Is Prothena Corporation PLC (PRTA) a Smart Choice in Biotechnology Wednesday? - InvestorsObserver

Fri, 27 Oct 2023
Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk - Simply Wall St

Mon, 16 Oct 2023
Prothena Reportedly Prepares for Potential Sale -October 16, 2023 ... -

Thu, 31 Aug 2023
Prothena to Participate in Upcoming Healthcare Conferences - Business Wire

Tue, 11 Jul 2023
Prothena to Present New Data from Alzheimer's Disease Programs ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 54 (M)
Held by Insiders 3.959e+007 (%)
Held by Institutions 4.7 (%)
Shares Short 4,390 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1175e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -52 %
Operating Margin 12.1 %
Return on Assets (ttm) -10.9 %
Return on Equity (ttm) -14.4 %
Qtrly Rev. Growth 5 %
Gross Profit (p.s.) 1123.4
Sales Per Share 3.20409e+008
EBITDA (p.s.) -1.85591e+008
Qtrly Earnings Growth -1.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 19.9
Price to Book value 0
Price to Sales 0
Price to Cash Flow 1.33
Stock Dividends
Dividend 0
Forward Dividend 6.5e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android